(MIT Technology Review) – In a bid to treat blindness, Life Biosciences will try out potent cellular reprogramming technology on volunteers.

ER-100 turns out to be the code name of a treatment created by Life Biosciences, a small Boston startup that Sinclair cofounded and which he confirmed today has won FDA approval to proceed with the first targeted attempt at age reversal in human volunteers. 

The company plans to try to treat eye disease with a radical rejuvenation concept called “reprogramming” that has recently attracted hundreds of millions in investment for Silicon Valley firms like Altos Labs, New Limit, and Retro Biosciences, backed by many of the biggest names in tech. 

The technique attempts to restore cells to a healthier state by broadly resetting their epigenetic controls—switches on our genes that determine which are turned on and off. (Read More)